Estrogen plays a meaningful but complex role in pelvic floor health. While declining estrogen during perimenopause and menopause can contribute to symptoms, research suggests estrogen deprivation alone may not directly predict pelvic floor muscle weakness. Hormone therapy, when tailored individually, is safe and effective for most women—and non-hormonal options exist too.
Many women and those assigned female at birth enter perimenopause with little more than a handful of assumptions about what’s happening in their bodies. Some of those assumptions are helpful. Many are not. When it comes to estrogen and the pelvic floor specifically, misinformation is widespread—and it can quietly steer people away from treatments that could genuinely improve their quality of life.
Estrogen is far more than a reproductive hormone. It supports your cardiovascular system, your bones, your brain, and yes, your pelvic floor. So when estrogen begins to decline—as it does during perimenopause and menopause—the effects ripple across the entire body. Understanding that complexity is the first step toward making empowered, informed decisions about your health.
This post breaks down the most common myths and the evidence-based facts about estrogen’s role in pelvic floor health, so you can walk into your next healthcare conversation with clarity and confidence.
What Is Estrogen, and What Does It Actually Do?
Estrogen is the primary female sex hormone, produced mainly by the ovaries. Most people associate it with reproduction—and while that’s accurate, estrogen’s influence extends well beyond fertility.
Estrogen plays a role in maintaining bone density, regulating cardiovascular function, supporting cognitive health, and sustaining the integrity of connective tissues throughout the body, including those in the pelvic region. Estrogen receptors exist throughout the pelvic floor, which is why hormonal shifts can influence how these muscles and tissues feel and function.
Recognizing estrogen’s broad role helps explain why menopause—which marks the end of estrogen production by the ovaries—can produce such a wide and sometimes surprising range of symptoms.
The Myths: What Gets Estrogen and the Pelvic Floor Wrong
Myth 1: Estrogen loss always causes pelvic floor muscle weakness
This is one of the most persistent beliefs in women’s health circles—and it’s more complicated than it sounds.
The assumption goes like this: as estrogen declines, pelvic floor muscles weaken. Therefore, estrogen deprivation is a direct, independent cause of pelvic floor dysfunction. Plausible? Yes. Accurate? Not quite.
A retrospective study published in PubMed examined 686 women attending a urogynecological clinic and found that on multivariate analysis, there was no significant association between menopausal age and pelvic floor muscle contractility. The study’s conclusion was direct: “Estrogen deprivation may not be an independent predictor of pelvic floor muscle contractility.”
This doesn’t mean estrogen is irrelevant to pelvic floor health. It means the relationship is far more nuanced than a simple cause-and-effect. Factors like age, BMI, childbirth history, and lifestyle all influence pelvic floor function—sometimes more than hormonal status alone.
Myth 2: Hormone Replacement Therapy (HRT) is too dangerous to consider
This myth has a very specific origin: a 2002 Women’s Health Initiative study that concluded HRT increased the risk of breast cancer, heart disease, and stroke. The findings triggered a near 50% decline in HRT use within just six months of publication.
What didn’t get as much attention? The methodological flaws that follow-up research identified. The 2002 study had focused almost exclusively on women who were, on average, 10 years post-menopause with an average age of 63—a demographic already at elevated cardiovascular risk. The study also evaluated only one delivery method: a daily oral pill combining estrogen and progestin, using formulations that have since largely been replaced.
The science has moved on considerably. Today, according to Ohio State University’s Wexner Medical Center, menopausal hormone therapy (MHT) is considered safe for most people when personal risk factors are taken into account, and when the specific type, formulation, and timing are planned carefully for each individual.
The fear has lingered far longer than the evidence warrants.
The Facts: What the Research Actually Shows
Fact 1: Estrogen decline during perimenopause and menopause is gradual—and wide-reaching
Menopause is defined as 12 consecutive months without a period, and the average age of menopause in the U.S. is 52, according to Yale Medicine. But the hormonal transition begins well before that—sometimes up to a decade earlier, during perimenopause.
During perimenopause, estrogen and progesterone levels don’t drop steadily. They fluctuate unpredictably, which makes diagnosis tricky and symptoms inconsistent. A blood test might look completely normal one day and show significant imbalances the next.
The effects of estrogen decline also go far beyond the pelvic floor. As Yale Medicine reports, declining estrogen has been linked to increased risk of cardiovascular disease—the leading cause of death for women in the U.S.—as well as a heightened risk of Alzheimer’s disease, osteoporosis, and sleep apnea. Estrogen plays protective roles in brain function, including promoting synaptic growth between neurons and reducing neuroinflammation. When those levels fall, those protections weaken.
Understanding this broader picture matters. Pelvic floor symptoms don’t exist in isolation.
Fact 2: Estrogen alone doesn’t determine pelvic floor strength
Returning to the PubMed study referenced earlier: among its 686 participants, the average BMI was 29 kg/m², and 60.6% were menopausal with a mean menopausal duration of 16 years. Despite this, estrogen deprivation did not independently predict pelvic floor muscle contractility on multivariate analysis.
What does this mean for you? Pelvic floor health is shaped by multiple converging factors—age, BMI, physical activity, childbirth history, and lifestyle habits among them. Estrogen matters, but attributing pelvic floor dysfunction solely to low estrogen oversimplifies a complex picture.
This also means that treatment approaches need to be equally multifaceted. Hormone support may be one piece of the puzzle, but pelvic floor physical therapy, targeted exercise, and lifestyle factors all play meaningful roles alongside it.
Fact 3: Hormone therapy can safely relieve symptoms—and it comes in many forms
When hormone therapy is appropriate, the good news is that it has evolved significantly since 2002. Ohio State University’s Wexner Medical Center outlines that MHT can be used during perimenopause—not just after menopause is complete—and that treatment is guided by symptoms, not solely by hormone level testing.
The myth that MHT always comes in pill form is also worth dispelling. Options now include:
- Transdermal patches
- Rub-on gels and sprays
- Vaginal rings
- Intrauterine devices (IUDs)
Each form carries a different risk and benefit profile. For women at higher risk of blood clots, for example, skin-absorbed therapies may be safer than oral options.
For women who cannot use hormones, non-hormonal options exist, including fezolinetant (Veozah), gabapentin, certain antidepressants, and behavioral modifications. No woman should feel that hormone therapy is her only path forward—or that it’s unavailable to her.
Breast cancer risk, for context: Ohio State reports that the risk associated with MHT is approximately one additional case per 1,000 uses per year—a risk comparable to that associated with obesity and low physical activity. This doesn’t mean risk should be dismissed, but it does mean risk should be assessed honestly, in the context of your personal and family history.
Navigating Menopause and Pelvic Health: What This Means for You
One of the most important principles in menopause care is this: treatment should be based on your symptoms and your individual health profile, not on a single hormone level result. Ohio State University confirms that checking hormone levels isn’t always necessary before beginning MHT, because levels can fluctuate dramatically during perimenopause and provide only a snapshot in time.
Personalized care is not optional—it’s essential.
There’s also a concerning gap in how healthcare providers are trained to address menopause. A 2023 survey cited by Yale Medicine found that over 90% of obstetrics and gynecology residency directors agreed that residents should have access to a standardized menopause curriculum—yet fewer than a third reported their programs actually offered one.
The market is responding, too. The global menopause market is projected to grow from $17.66 billion in 2024 to $27.63 billion by 2033, reflecting the growing demand for better diagnostic tools, pharmaceutical options, and educational resources. Women are no longer willing to accept inadequate answers—and they shouldn’t have to.
Frequently Asked Questions
Does low estrogen always cause pelvic floor problems?
Not necessarily. While estrogen receptors exist throughout the pelvic floor and declining estrogen can contribute to tissue changes and symptoms, research published in PubMed found that estrogen deprivation may not be an independent predictor of pelvic floor muscle contractility. Age, BMI, childbirth history, and physical activity also play significant roles.
Is hormone therapy safe for pelvic floor and menopause symptoms?
For most women, yes. According to Ohio State University’s Wexner Medical Center, MHT is safe for most people when personal risk factors are considered, and the type, formulation, and timing are planned individually. Women who cannot use hormones also have non-hormonal options available.
When should I start hormone therapy for menopause symptoms?
Research suggests hormone therapy is most beneficial when started within 10 years of menopause or before age 60. MHT can also be used during perimenopause, not only after menopause. Critically, treatment decisions should be based on your symptoms and health history—not on a specific hormone level. Talk to your OB/GYN about your specific health history.
What non-hormonal options exist for pelvic floor and menopause symptoms?
Non-hormonal options include fezolinetant (Veozah), gabapentin, certain antidepressants, and behavioral modifications. Pelvic floor physical therapy is also an evidence-informed approach that can address muscle function, regardless of hormonal status.
Do I need a hormone blood test before starting treatment?
Not always. As Ohio State notes, hormone levels fluctuate significantly during perimenopause and a single test captures only one moment in time. Most providers treat based on symptoms rather than waiting for lab confirmation. Your provider may order tests to rule out other causes, but symptoms remain the primary guide.
Take the Next Step Toward Better Pelvic Health
Estrogen’s role in pelvic floor function is real, but it’s one variable within a larger, more intricate system. Estrogen deprivation alone does not automatically predict pelvic floor dysfunction—and hormone therapy combined with pelvic floor therapy, when carefully selected and individually tailored, is a safe and effective option for most women experiencing menopause symptoms.
What matters most is that you have access to accurate information and personalized support. Your symptoms are valid. Your concerns deserve thorough answers.
If you’re experiencing pelvic floor issues or have questions about how estrogen may be affecting your pelvic health, reach out to me, Pelvic Floor Therapist Sherryl DeVries, for a personalized consultation. I can help you understand what’s happening in your body and develop a targeted plan to support your pelvic health at every stage of life. Book your appointment today.